Clinical Trial Update: An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma [Phase 3]

View source ↗

Summary

Phase 3 trial update comparing three inhaled corticosteroid/long-acting beta-agonist regimens for adults and adolescents with persistent asthma; results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder (fluticasone furoate/vilanterol)
• Fluticasone Propionate 250 mcg Inhalation Powder (fluticasone propionate)
• Fluticasone propionate-salmeterol 250/50 mcg inhalation powder (Fluticasone propionate; Salmeterol xinafoate)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2017-06-12